GlassScriptPhysician profile
Uzma Syeda
NPI 1174562565
$10,035.22
in general payments reported to CMS, 2019-2025
37 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $509 · 2021: $1,113 · 2022: $1,720 · 2023: $1,967 · 2024: $1,518 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $42.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,545.30 |
| Education | $42.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,263.01 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $1,632.43 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $1,025.57 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $885.27 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $838.10 | 2020-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $709.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $429.70 | 2019-2025 | Orencia |
| Lilly USA, LLC | $425.95 | 2019-2024 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $185.85 | 2021-2025 | |
| Horizon Therapeutics Plc | $174.08 | 2019-2022 | |
| Organon LLC | $160.19 | 2023-2025 | Hadlima, Renflexis |
| Pfizer INC. | $151.26 | 2019-2025 | |
| Radius Health, INC. | $145.08 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.75 | 2022-2025 | Cyltezo, Ofev |
| Aurinia Pharma U.S., INC. | $127.14 | 2021-2023 | Lupkynis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medexus Pharma, INC. | $90.02 | 2019-2020 | |
| Genzyme Corporation | $89.77 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $89.02 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Fresenius Kabi USA, LLC | $65.49 | 2023-2025 | Idacio, Tyenne |
| Alexion Pharmaceuticals, INC. | $48.06 | 2024 | Strensiq |
| Celltrion USA INC. | $42.37 | 2023 | Yuflyma |
| Almatica Pharma LLC | $35.72 | 2022 | |
| Octapharma USA, INC. | $32.05 | 2023 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals International, Plc | $27.18 | 2024 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $26.66 | 2023 | Truxima |
| Merck Sharp & Dohme LLC | $25.24 | 2019 | |
| Medtronic, INC. | $23.13 | 2023 | Intellis Adaptivestim |
| Antares Pharma, INC. | $21.34 | 2019 | |
| Tonix Medicines, INC. | $21.28 | 2025 | Tonmya |
| Mylan Institutional INC. | $20.95 | 2023 | |
| Genentech USA, INC. | $20.49 | 2021 | |
| Scilex Pharmaceuticals INC. | $19.02 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.30 | 2022 | |
| Hikma Pharmaceuticals USA | $15.80 | 2019 | |
| Integra Lifesciences Corporation | $14.57 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Syeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.